Multi-centre phase II, randomized open-label clinical trial on the therapeutic use of Rexmyelocel T (REX 001) in non-diabetic patients with critical chronic ischaemia of lower limbs

Trial Profile

Multi-centre phase II, randomized open-label clinical trial on the therapeutic use of Rexmyelocel T (REX 001) in non-diabetic patients with critical chronic ischaemia of lower limbs

Recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Aug 2016

At a glance

  • Drugs Rexmyelocel T (Primary)
  • Indications Peripheral ischaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 Aug 2016 This study is expected to complete by early 2016, according to data available on company website. (refer http://www.rexgenero.com/?page_id=3510)
    • 04 Aug 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top